The Emory Molecular Interaction Center for Functional Genomics (MicFG), with its expertise in high throughput technologies for the study of protein-protein interactions (PPI), productive track record of innovative HTS assay development for chemical lead discovery, and proven cancer genomics mining, database, and data integration capabilities, seeks to become a node in the NCI Cancer Target Discovery and Development (CTDD) Network. Genomic alterations in various tumor types, as revealed by cancer genomics initiatives such as The Cancer Genome Atlas (TCGA), often lead to re-wired protein-protein interaction networks, which in turn drive tumor initiation and progression. Thus, identifying prominent PPI nodes and networks among oncoproteins and tumor suppressors as enriched by various genomics datasets and the validation of their critical roles in tumorigenesis and progression are expected to reveal an entirely new class of PPI-based cancer targets for therapeutic development. To achieve this goal, we propose to utilize our established high throughput PPI technologies to interrogate cancer genomics information through a team science approach (i) to rapidly establish oncogenic PPI networks of selected cancer types based on TCGA and other genomic datasets, (ii) to validate functional roles of key PPI nodes or hubs in tumorigenesis and progression, (iii) to develop HTS assays for critical tumor-associated PPIs to enrich the therapeutic target pipeline of the NCI and the drug discovery field, and (iv) to leverage our informatics capability for genomics data mining for prioritized PPI mapping, functional PPI validation, and trans-network data sharing and collaboration.
We aim to bridge the gap between vast genomic datasets and therapeutic discovery by establishing and interrogating the cancer PPI target space. With our PPI expertise and state-of-the-art high throughput technologies, which are highly adaptable to a variety of outputs, we intend to function as an active, synergistic member in collaborative trans- Network projects.
While current drug discovery is primarily focused on a single molecular target, such as a kinase or a transmembrane receptor, our project intends to target the interface between two proteins (protein-protein interactions) to disrupt the signaling networks that cancers rely on. Genomic alterations in cancer often lead to re-wired protein interaction networks. Interrogation of these cancer-associated protein-protein interactions with high throughput methods offers new opportunities for the discovery of novel therapeutics.
|Havel, J J; Li, Z; Cheng, D et al. (2015) Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway. Oncogene 34:1487-98|
|Long, Qi; Xu, Jianpeng; Osunkoya, Adeboye O et al. (2014) Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res 74:3228-37|
|Johns, Margaret A; Meyerkord-Belton, Cheryl L; Du, Yuhong et al. (2014) The Emory Chemical Biology Discovery Center: leveraging academic innovation to advance novel targets through HTS and beyond. Comb Chem High Throughput Screen 17:290-6|
|Ivanov, Andrei A; Khuri, Fadlo R; Fu, Haian (2013) Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci 34:393-400|